AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors

被引：0
|
作者：
Dowlati, A. [1 ]
Richardson, D. L. [2 ]
Lorusso, P. [3 ]
Spira, A. I. [4 ]
Bashir, B. [5 ]
Hirmand, M. [6 ]
Mehta, M. [6 ]
Patel, M. R. [7 ]
机构：
[1] Case Western Reserve Univ, Div Hematol & Oncol, Dept Med, Cleveland, OH USA
[2] Univ Oklahoma, Gynecol Oncol Sect, Dept Obstet & Gynecol Sect Gynecol Oncol, Stephenson Canc Ctr, Oklahoma City, OK USA
[3] Yale Univ, Dept Med Oncol, Yale Comprehens Canc Ctr, Sch Med, New Haven, CT USA
[4] Virginia Canc Specialists, VCS Res Inst, Fairfax, VA USA
[5] Thomas Jefferson Univ, Div Solid Tumors, Dept Med Oncol, Sidney Kimmel Canc Ctr, Philadelphia, PA USA
[6] Avenzo Therapeut Inc, Clin Dev, San Diego, CA USA
[7] Florida Canc Specialists, Drug Dev Unit, Sarasota, FL USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.386
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
439TiP
引用
收藏
页码：S405 / S405
页数：1
相关论文
共 50 条
  • [41] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [42] Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.
    De Mattos-Arruda, Leticia
    Siu, Lillian L.
    Cortes, Javier
    Berge, Yann
    Razak, Albiruni R. A.
    Ahnert, Jordi Rodon
    Cottura, Ewa
    Bedard, Philippe
    Akimov, Mikhail
    Lu, Hong
    Pain, Scott
    Kaag, Audrey
    Delord, Jean-Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Jeffrey R. Infante
    David S. Mendelson
    Howard A. Burris
    Johanna C. Bendell
    Anthony W. Tolcher
    Michael S. Gordon
    Heidi H. Gillenwater
    Shirin Arastu-Kapur
    Hansen L. Wong
    Kyriakos P. Papadopoulos
    Investigational New Drugs, 2016, 34 : 216 - 224
  • [44] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [45] Updated results from a phase I, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors
    Price, T. J.
    Prenen, H.
    Lugowska, I.
    Falchook, G. S.
    Monzon, J. G.
    Arkenau, H. T.
    Chawla, S. P.
    Hui, M. N.
    Kuboki, Y.
    Dziadziuszko, R.
    Ozawa, Y.
    Fernandez, M. E. Elez
    Lima, C. S. P. Rocha
    Subbiah, V.
    Tan, D. S. W.
    Wang, K.
    Hindoyan, A.
    Shi, W.
    Kistler, M.
    Sadraei, N. Hashemi
    ANNALS OF ONCOLOGY, 2021, 32 : S1440 - S1442
  • [46] First-in-human, dose-escalation phase I trial of intratumoral (IT) CyPep-1 in patients (pts) with advanced solid tumors
    Eskens, F.
    Opdam, F.
    Gort, E.
    Gelderblom, H.
    Prestegarden, L.
    Pico-Navarro, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S758 - S758
  • [47] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Keedy, Vicki L.
    Lenz, Heinz-Josef
    Saltz, Leonard
    Whisenant, Jennifer G.
    Berlin, Jordan D.
    Camacho, Luis H.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 860 - 868
  • [48] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Vicki L. Keedy
    Heinz-Josef Lenz
    Leonard Saltz
    Jennifer G. Whisenant
    Jordan D. Berlin
    Luis H. Camacho
    Investigational New Drugs, 2018, 36 : 860 - 868
  • [49] First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
    Hassan, Raffit
    Blumenschein, George R., Jr.
    Moore, Kathleen N.
    Santin, Alessandro D.
    Kindler, Hedy L.
    Nemunaitis, John J.
    Seward, Shelly M.
    Thomas, Anish
    Kim, Stella K.
    Rajagopalan, Prabhu
    Walter, Annette O.
    Laurent, Dirk
    Childs, Barrett H.
    Sarapa, Nenad
    Elbi, Cem
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1824 - +
  • [50] A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors
    Ahnert, Jordi Rodon
    Spigel, David R.
    Kremer, Jill
    Jin, Leah
    Benhadji, Karim Adnane
    Gil, Maciej
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345